Assessment of Cardioversion Using Transesophageal Echocardiography II (ACUTE II)
The Use of Enoxaparin Compared to Unfractionated Heparin for Short Term Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing TEE Guided Cardioversion: Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) II Randomized Multicenter Study
Sponsor: Sanofi
A PHASE4 clinical study on Atrial Fibrillation, this trial is completed. The trial is conducted by Sanofi and has accumulated 5 data snapshots since 1999. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Dec 1999
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sanofi
- The Cleveland Clinic
For direct contact, visit the study record on ClinicalTrials.gov .